CHARIOT / BCT 1702: A phase II study evaluating efficacy and safety of Ipilimumab and Nivolumab with neoadjuvant weekly paclitaxel after anthracycline based chemotherapy in high-risk primary triple negative breast cancer, followed by definitive surgery and one year total duration of Nivolumab

  • White, Michelle (Primary Chief Investigator (PCI))

Project: Research

Project Details

Project Description

NMA HREC Reference Number: HREC/17/PMCC/236 (ERM Project ID: 38394)
NMA SSA Reference Number: SA/38394/MonH-2018-157007(v1)
Monash Health Ref: RES-18-0000-769X
StatusFinished
Effective start/end date21/12/18 → 20/12/23